(Q47791327)

5 February 2018

title

Increased expression of collagen XVIII and its prognostic value in nonsmall cell lung carcinoma (English)

1 reference

5 February 2018

author name string

Hao Chang

1

1 reference

5 February 2018

Toshihiko Iizasa

2

1 reference

5 February 2018

Kiyoshi Shibuya

3

1 reference

5 February 2018

Akira Iyoda

4

1 reference

5 February 2018

Makoto Suzuki

5

1 reference

5 February 2018

Yasumitsu Moriya

6

1 reference

5 February 2018

Tian-Ling Liu

7

1 reference

5 February 2018

Takaki Hiwasa

8

1 reference

5 February 2018

Kenzo Hiroshima

9

1 reference

5 February 2018

Takehiko Fujisawa

10

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 April 2004

1 reference

5 February 2018

published in

Cancer

1 reference

5 February 2018

volume

100

1 reference

5 February 2018

issue

8

1 reference

5 February 2018

page(s)

1665-1672

1 reference

5 February 2018

K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

Microvessel quantitation in invasive breast cancer by staining for factor VIII-related antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

'Tumour volume' as a predictor of survival after resection of non-small-cell lung cancer (NSCLC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Small cell lung cancer: current therapy and promising new regimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

The future of prognostic factors in outcome prediction for patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Clinical tumour markers in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Transplacental carcinogenesis by stilbestrol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Relation of neovascularisation to metastasis of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Tumor angiogenesis in human lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Secreted cathepsin L generates endostatin from collagen XVIII

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Collagen XVIII is localized in sinusoids and basement membrane zones and expressed by hepatocytes and activated stellate cells in fibrotic human liver

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

The role of collagen-derived proteolytic fragments in angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Serum endostatin correlates with progression and prognosis of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Revisions in the International System for Staging Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Increase in ultraviolet sensitivity by overexpression of calpastatin in ultraviolet-resistant UVr-1 cells derived from ultraviolet-sensitive human RSa cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Endostatin induces endothelial cell apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Phase I study of recombinant human endostatin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Identification of three N-terminal ends of type XVIII collagen chains and tissue-specific differences in the expression of the corresponding transcripts. The longest form contains a novel motif homologous to rat and Drosophila frizzled proteins.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Serum endostatin levels are elevated in patients with soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Circulating angiogenic cytokines as tumour markers and prognostic factors in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Life without perlecan has its problems

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Immunohistochemical expression of angiogenesis-related markers in oral squamous cell carcinomas with multiple metastatic lymph nodes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20156

7 January 2021

Identifiers

DOI

10.1002/CNCR.20156

1 reference

5 February 2018

1 reference

5 February 2018